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Activation of prodrugs in tumors (e.g., by bioreduction in hypoxic zones) has the potential
to generate active metabolites that can diffuse within the tumor microenvironment. Such
“bystander effects” may offset spatial heterogeneity in prodrug activation but the relative
importance of this effect is not understood. Here, we quantify the contribution of bystander
effects to antitumor activity for the first time, by developing a spatially resolved pharmacoki-
netic/pharmacodynamic (SR-PK/PD) model for PR-104, a phosphate ester pre-prodrug that
is converted systemically to the hypoxia-activated prodrug PR-104A. Using Green’s func-
tion methods we calculated concentrations of oxygen, PR-104A and its active metabolites,
and resultant cell killing, at each point of a mapped three-dimensional tumor microregion.
Model parameters were determined in vitro, using single cell suspensions to determine
relationships between PR-104A metabolism and clonogenic cell killing, and multicellular
layer (MCL) cultures to measure tissue diffusion coefficients. LC-MS/MS detection of active
metabolites in the extracellular medium following exposure of anoxic single cell suspen-
sions and MCLs to PR-104A confirmed that metabolites can diffuse out of cells and through
a tissue-like environment.The SR-PK/PD model estimated that bystander effects contribute
30 and 50% of PR-104 activity in SiHa and HCT116 tumors, respectively.Testing the model
by modulating PR-104A-activating reductases and hypoxia in tumor xenografts showed
overall clonogenic killing broadly consistent with model predictions. Overall, our data sug-
gest that bystander effects are important in PR-104 antitumor activity, although their reach
may be limited by macroregional heterogeneity in hypoxia and reductase expression in
tumors.The reported computational and experimental techniques are broadly applicable to
all targeted anticancer prodrugs and could be used to identify strategies for rational prodrug
optimization.
Keywords: anticancer prodrugs, hypoxia-activated prodrugs, PR-104, bystander effect, extravascular drug transport,
multicellular layers, pharmacokinetic/pharmacodynamic modeling, NADPH:cytochrome P450 oxidoreductase
INTRODUCTION
Intra-tumor heterogeneity is a fundamental barrier to all tar-
geted therapies (1). One of the attractive features of prodrugs
that are activated within tumors is their potential for decoupling
targeting and pharmacodynamic effect through diffusion of active
metabolites from prodrug-activating cells to surrounding untar-
geted cells. These bystander effects are thought to be important
for monotherapy activity of targeted anticancer prodrugs (2–4),
including hypoxia-activated prodrugs (HAP) activated by biore-
duction in hypoxic regions (5–7). Bystander effects may also be
important for activity of HAP in combination with agents that
spare hypoxic cells, such as ionizing radiation; activation of most
HAP is inhibited by O2 concentrations too low to effect radiosen-
sitization (8–11), so there is likely a subpopulation of radiore-
sistant hypoxic cells that can only be killed by HAP if bystander
metabolites diffuse from severely hypoxic regions (5). However,
the contribution of bystander effects to the anticancer activity of
prodrugs, either as monotherapy or in combination settings, is
poorly understood.
The purpose of this study was to investigate the role of
bystander effects in the antitumor activity of the dinitrobenzamide
mustard PR-104, a clinical-stage HAP (12). PR-104 was chosen
because its mechanism of action is well understood (7), its active
metabolites are known to be capable of diffusing from cells (13)
and thus are expected to elicit a bystander effect, and validated
analytical methods for their quantitation are available (14). The
phosphate ester moiety of PR-104 is rapidly converted systemi-
cally to the corresponding alcohol PR-104A (13, 15), which is a
prodrug that is activated by reduction of a nitro group to the
corresponding hydroxylamine (PR-104H) and amine (PR-104M),
both of which are DNA crosslinking cytotoxins (16, 17). Hypoxia-
selective activation can be effected by one-electron-reductases
such as NADPH:cytochrome P450 oxidoreductase (POR) (18, 19)
via formation of a nitro radical that is further reduced to PR-104H
and PR-104M under hypoxia, but is rapidly back-oxidized in the
presence of O2. Half-maximal inhibition of PR-104A cytotoxicity
was found to require only ∼0.13µM O2 in SiHa cell suspensions
(20), which is well below that for half-maximal radiosensitization
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[∼4µM O2, (21)]. In addition, to this highly O2-sensitive one-
electron activation mechanism, two-electron reduction by aldo-
keto reductase 1C3 (AKR1C3) provides an O2-insensitive pathway
to the same cytotoxic metabolites in cells with high AKR1C3
expression (22). PR-104 has shown striking single-agent activity
in several human tumor xenografts (13, 16, 22, 23), which may
partially be due to bystander effects.
Here, we utilize a spatially resolved pharmacokinetic/
pharmacodynamic (SR-PK/PD) modeling approach to dissect
the contribution of bystander effects (whether from hypoxia-
dependent or hypoxia-independent activation) to PR-104 antitu-
mor activity. Our approach builds on the earlier development of an
SR-PK/PD model for the well-studied HAP tirapazamine that used
Green’s function methods to model diffusion and reaction of O2
and tirapazamine in a mapped three-dimensional tumor microre-
gion (24). This model, validated using a series of tirapazamine
analogs, demonstrated that rapid bioreductive metabolism during
diffusion into hypoxic regions can limit hypoxic cell killing. This
led us to use SR-PK/PD modeling to identify tirapazamine analogs
with improved extravascular transport and antitumor activity in
xenograft (25). The SR-PK/PD models for tirapazamine analogs
did not require inclusion of bystander effects, consistent with evi-
dence that the active metabolites are free radicals that do not
escape the cell of origin (26). An analogous SR-PK/PD model
for PR-104 under-predicted activity in SiHa tumor xenografts,
which we suggested might reflect the failure to consider bystander
effects (20).
In the present study, we develop a PR-104 SR-PK/PD model
that explicitly considers bystander effects for the first time, by
incorporating reaction and diffusion of the active metabolites of
PR-104A (Figure 1). Parameters of the model are determined
experimentally using single cell suspensions to develop a cellular
PK/PD model that defines relationships between PR-104A metab-
olism and reproductive cell death (measured as clonogenic cell
killing), and multicellular layer (MCL) cultures (27) to deter-
mine extravascular transport properties of PR-104A, PR-104H,
and PR-10M. These parameters are used to calculate the spatial
distribution of PR-104A and its active metabolites, and result-
ing cell killing, in a virtual tumor microregion that is based
on an experimentally observed vascular network structure in a
FaDu tumor. This relatively complex approach was used because
simpler models assuming regularly spaced vascular geometries
under-estimate the spatial heterogeneity of tumor oxygenation
(28). Bystander killing is expected to be sensitive to the spatial O2
distribution because it critically depends on the distance between
severely hypoxic PR-104A-activating cells and bystander target
cells at intermediate O2 concentrations. We evaluate the SR-PK/PD
model by testing its ability to predict measured PR-104 activity
in different tumor xenograft models and utilize it to investigate
the relative importance of bystander effects in PR-104 antitumor
activity.
MATERIALS AND METHODS
THE PR-104 SR-PK/PD MODEL
Tissue gradients of oxygen, PR-104A, PR-104H, and PR-104M
were calculated in a digitized three-dimensional (3D) tumor
microvascular network using Green’s function methods (24, 29).
FIGURE 1 | Approach for the development of an SR-PK/PD model. The
SR-PK/PD model incorporates several different sub-models to calculate O2,
prodrug and drug AUC (PK) and killing (PD) in a 3D tumor microregion. The
cellular PK model describes intra- and extracellular concentration-time
profiles of prodrug and drug measured in single cell suspensions. The
cellular PK/PD model defines the relationship between cell kill and
intracellular drug AUC based on single cell suspension data. Transport of
prodrug and drug through MCLs was measured to build a (pro)drug
transport model that calculates tissue transport using diffusion coefficients
and the parameters of the cellular PK model. The O2 transport model, which
is informed by the measured binding of 2-nitroimidazole hypoxia markers in
tumor xenografts, calculates O2 concentrations in the 3D tumor
microregion. The (pro)drug transport model then calculates AUC of prodrug
and drug at each point of the microregion, using measured PK in mice to
define inflow to the network. This information is used by the cellular PK/PD
model to estimate cell kill at each position.
The network was derived by mapping microvascular anatomy as
well as direction and velocity of blood flow in a region of a sub-
cutaneous FaDu tumor xenograft (990µm× 810µm× 150µm)
grown in a mouse dorsal window chamber (30), and is represented
by cylindrical segments (see Figure 1). The vessel walls are treated
as part of the tissue space, which is represented as a homoge-
neous medium. Steady-state conditions are assumed. The model
was implemented using a customized version of the Green’s func-
tion method written in Visual C++ (Microsoft Visual Studio 2010
Express).
Calculation of oxygenation in the tumor microregion
Convective transport of oxygen along vessel segments and diffu-
sion into the surrounding tissue was calculated based on estimates
for blood content, tissue diffusion and consumption of O2 (29).
The O2 content of inflowing blood was adjusted to achieve a
hypoxic fraction in the tumor microregion that is similar to the
measured fraction of HCT116 or SiHa tumor xenografts staining
positive for the 2-nitroimidazole hypoxia probe pimonidazole (22)
or EF5 (this study). For this purpose a threshold of 1µM O2 was
chosen based on the reported O2-dependence of 2-nitroimidazole
binding (31, 32). O2 transport parameters are given in Table S1 in
Supplementary Material.
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Calculation of pharmacokinetics in the tumor microregion
Inflow of PR-104A, PR-104H, and PR-104M to the tumor
microvascular network was defined by the plasma
pharmacokinetics measured after administration of 562µmol/kg
PR-104 to CD-1 nude (13, 33) or NIH-III nude mice (this study).
The active metabolites are present in plasma due to activation of
PR-104A in the liver (33). Unbound area under the concentration-
time curve (AUC) was used as a time-independent exposure
variable compatible with Green’s function formalism.
Based on the reported high permeability of tumor blood vessels
(34, 35), vessel walls were modeled as offering negligible resistance
to radial flux of PR-104A, PR-104H, and PR-104M (by setting the
intravascular resistance constant (29) to a low value of 0.1 s/µm).
Extravascular transport in the tumor tissue was calculated using
a 2-compartment (pro)drug transport model (Figure 2) with
concentrations in the extracellular compartment (Eq. 1) and the
intracellular compartment (Eq. 2) calculated as follows:
ϕe
∂CeN
∂t
= DN∇2CeN − ϕi (keiNCeN − kieNCiN )
− ϕekinstabNCeN (1)
ϕi
∂CiN
∂t
= ϕi (keiNCeN − kieNCiN )− ϕikinstabNCiN
− ϕikmetNCiN + rN (2)
C e and C i are the extracellular and intracellular concentrations,
respectively, of PR-104A, PR-104H, or PR-104M (denoted by
N =A,H, or M ),ϕi and ϕe are the intra- and extracellular volume
fractions with ϕe = 1−ϕi , k ieN and keiN are the rate constants for
transfer from the intracellular to the extracellular compartment
and vice versa, DN is the diffusion coefficient in the extracellular
compartment, 52 is the Laplacian operator, kmetN and k instabN
are the rate constants for metabolism and instability, respectively,
and rN is the rate of metabolic production of PR-104H from PR-
104A or PR-104M from PR-104H. The rate constant for PR-104A
metabolism, kmetA, is O2-dependent:
kmetA = f [(O2)] kmetA,max
=
(
kmetA,min
kmetA,max
+
(
1− kmetA,min
kmetA,max
)
KO2
KO2 + [O2]
)
kmetA,max
(3)
where f ([O2]) is the ratio of prodrug activation at O2 concentra-
tion [O2] to that under anoxia, KO2 is the O2 concentration for
half-maximum PR-104A activation and kmetA,max and kmetA,min
are the maximum (anoxic) and minimum (aerobic) rate constants
for PR-104A metabolism.
Calculation of cell killing in the tumor microregion
Surviving fraction (SF) at each point of the tumor microregion
was calculated from intracellular PR-104H+M AUC (AUCH+M)
to account for bystander effects resulting from metabolite diffu-
sion (“+bystander model”; Eq. 4), but from intracellular PR-104A
AUC (AUCA) when assuming that only prodrug-activating cells
are killed (“no-bystander model”; Eq. 5). For the former, PR-104H
and PR-104M were assumed to be equally potent, based on their
similar inhibition of proliferation of several cell lines (17).
Log cell kill = − log SF = AUCH+M
AUC10H+M
(4)
Log cell kill = f ([O2]) AUCA
AUC10A
(5)
AUC10A and AUC10H+M are the values of AUCA (under anoxia)
and AUCH+M (O2-independent), respectively, for 10% SF, and
f([O2]) (see Eq. 3) defines the O2-dependence of PR-104A
cytotoxicity.
Cell survival after radiation treatment was calculated as
described (24). Briefly, a linear-quadratic (LQ) model was used:
− log SF = αHOERαDr + βH
(
OERβDr
)2
(6)
where SF is the cell SF following radiation treatment, Dr the
radiation dose, and αH and βH are the proportionality con-
stants for the LQ model under hypoxia. The O2 enhancement
ratio OER (radiation dose under hypoxia divided by the dose
for the same effect at a given oxygen concentration [O2]) is
calculated by:
OERi = OERi,max [O2]+ Kms
[O2]+ Kms (7)
where i denotes α or β, OERi,max is the maximal O2 enhance-
ment ratio and Kms the O2 concentration for half-maximal
radiosensitivity.
The SF from both radiation and prodrug at each point of the
tumor microregion was calculated from the sum of log cell kill due
to drug and radiation alone.
Averaging SF over the whole tumor microregion gave the overall
SF that was used for calculation of overall log cell kill. PR-104-
induced cell kill in addition to radiation was calculated as the
difference between overall log cell kill by PR-104+ radiation and
log cell kill by radiation alone.
COMPOUND FORMULATION
PR-104 and its metabolites (PR-104A, PR-104H, and PR-10M),
and their stable isotope internal standards were synthesized as
described (33). EF5 was a gift from the National Cancer Insti-
tute (Bethesda, MD, USA). FSL-61 was synthesized as reported
(36). All compounds had a purity of >90% by HPLC except PR-
104M (86%) and PR-104M-d4 (84%). In vitro experiments used
frozen (−80°C) stock solutions in DMSO or acetonitrile, diluted
at least 100-fold in culture medium. For in vivo studies PR-104
was formulated as described (13).
CELL CULTURE
Origins and monolayer culture of parental cell lines are described
elsewhere (19). The expression vector F279-V5 [constructed from
pIRES-P (37) and pcDNA6.2V5DEST (Invitrogen)] containing
a soluble version of the human POR gene (lacking the first
180 bp encoding the N-terminal endoplasmic reticulum mem-
brane anchor) was prepared by Gateway cloning and used to
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FIGURE 2 | Schematic representation of the cellular PK/PD and (pro)drug
transport models. The (pro)drug transport model describes PR-104A,
PR-104H, and PR-104M concentrations in the extracellular and intracellular
compartments. Transfer between the compartments is defined by rate
constants k ei N and k ieN, where N refers to each compound. Loss of PR-104A,
PR-104H, and PR-104M by non-enzymatic processes (defined by k instabN; not
shown) is assumed to occur in both compartments, while drug metabolism
(defined by kmetN) is restricted to the intracellular compartment. In the
extracellular compartment compounds can diffuse as defined by their
diffusion coefficients DN (double-headed arrows). The cellular PK/PD model
determines cell kill resulting from exposure to PR-104H plus PR-104M (Eq. 4)
while the linear-quadratic model calculates radiation-induced killing. The O2
transport model calculates convective transport of oxygen along vessel
segments and diffusion into the surrounding tissue as described (29) and
does not distinguish extra- and intracellular compartments. Arrows in blue
indicate O2-dependent processes.
transfect HCT116/wild type (WT) cells using reported methods
(22). The stable clonal cell line HCT116/sPOR#6 was selected
with puromycin as described (38) and grown in the presence of
3µM puromycin. Multicellular spheroids were initiated by seeding
105 cells in bacteriological 100 mm dishes, grown for 3 days, then
transferred to spinner flasks and grown for an additional 7 days
in αMEM containing 10% FBS and 1% penicillin/streptomycin.
Spheroids were enzymatically dissociated by incubation with
0.25% trypsin/EDTA in saline for 10–15 min, followed by incu-
bation with 0.1 mg/ml DNase for 2–10 min. MCLs were grown
by seeding 106 cells on microporous support membranes as
described (39).
CELLULAR PK/PD STUDIES
Intra/extracellular partitioning, (pro)drug metabolism and cyto-
toxicity were assessed in single cell suspensions as described (40).
Briefly, single cells in αMEM without serum (10 ml at ∼2× 106
cells/ml) were magnetically stirred in glass vials gassed with 5%
CO2/95% N2 (<10 ppm O2) or 5% CO2/95% air (20% O2).
Following equilibration for 1 h, (pro)drug [or DMSO alone to
determine control plating efficiency (PE)] was introduced and
1 ml samples were transferred to ice-cold glass vials at intervals.
Samples were used to evaluate clonogenic cell survival, and extra-
and intracellular drug concentrations.
For the latter, cells and medium were separated by centrifu-
gation (12,000 g, 30 s) followed by a brief second spin (12,000 g,
15 s) to remove excess media. Extracellular samples (super-
natants extracted with one volume of cold acidified methanol
(methanol:ammonium acetate:acetic acid 1000:3.5:0.2, v/w/v)
containing 1µM PR-104A-d4 and 0.3µM of PR-104H-d4 and
PR-104M-d4) and extracted cell pellets (80µl of the above extrac-
tion solvent per pellet, vortex mixed for 30 s) were frozen at−80°C.
Subsequently, thawed cell extracts were centrifuged (13,000 g, 4°C,
5 min) and supernatants were diluted in an equal volume of cold
αMEM to prepare intracellular samples, which were stored at
−80°C until LC-MS/MS analysis. To correct for the contribu-
tion from extracellular medium in cell pellets, the cell-excluded
marker 3H-mannitol was used. Cell suspensions were transferred
to microcentrifuge tubes containing 1% (v/v) of 10 pM 3H-
mannitol (20C i/mmol; American Radiolabeled Chemicals Inc.,
USA). Extracellular and intracellular samples were prepared as
above and 25µl aliquots were mixed with 3 ml of Emulsifier-
SafeTM water-accepting scintillant (3 ml; PerkinElmer, Torrance,
CA, USA) for scintillation counting (Packard Tricarb Scintillation
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Analyzer). The fraction of extracellular water in the cell extract (α)
can be calculated from the 3H-mannitol counts per microliter of
the intracellular and extracellular samples:
α =
3H−mannitol in intracellular sample
3H−mannitol in extracellular sample
= Vec
Vt
= Vec
Vsol + Vec + Vc (8)
with the total volume V t of the cell extract being composed of
the volume of extraction solvent V sol, the volume of extracellular
water V ec, and the cellular volume of the cell pellet V c. The latter
was derived by multiplying median cell volume by the cell number
(both parameters determined using an electronic cell counter (Z2
Coulter Counter; Beckman Coulter™, USA). The contribution of
V ec and V c is minor, together representing ∼ 4% of V t. Intra-
cellular concentrations of analytes were estimated by using V ec to
subtract the contribution of extracellular analytes from the total
analytes measured in cell pellet extracts.
Area under the concentration-time curves were calculated from
concentration-time profiles using the trapezoidal rule. The rela-
tionship between tumor cell survival and drug or prodrug AUC
was determined by fitting Eqs 4 or 5 [with f ([O2])= 1] to the data
using Microsoft Excel 2007.
MCL STUDIES
Multicellular layers were placed between a donor and a receiver
compartment (Figure 1) and equilibrated for at least 1 h under
flowing 5% CO2/95% O2 (oxia) or 5% CO2/95% N2 (anoxia).
PR-104A or PR-104H was added to the donor compartment along
with∼0.4µM 14C-urea (2.183 GBq/mmol; Amersham, Australia)
to determine MCL thickness using the known diffusion coefficient
of 14C-urea in SiHa (41) and HCT116 (39) MCLs. At intervals,
100µl was sampled from each compartment for liquid scintillation
counting, and for LC-MS/MS analysis of PR-104A and metabo-
lites. For the latter samples were processed as described in Section
“Cellular PK/PD Studies” for extracellular samples from cellular
PK/PD studies.
PARAMETER ESTIMATION
All model parameters were determined by fitting Eqs 1 and 2 (with-
out including spatial variation) to the concentration-time profiles
of PR-104A, PR-104H, and PR-104M measured in cellular PK/PD
and MCL studies.
Values of kmetN, k ieN, and keiN for PR-104A, PR-104H, and PR-
104M were simultaneously fitted to cellular PK data, with D set to
0,ϕi set to the cell volume fraction in single cell suspensions (calcu-
lated from median cell volume and cell density as measured with an
electronic cell counter in each experiment) and k instabN fixed at the
values determined after addition of the respective compound to
culture medium without cells. Non-linear mixed effects modeling
(Non-MEM version 7, ICON Development Solutions) using first-
order conditional estimation with interaction and ADVAN13 to
solve the differential equations was used, allowing for variability of
parameters to account for intra- and inter-experiment variability.
Drug transport in MCLs was modeled as one-dimensional dif-
fusion with reaction in the series of compartments (donor, MCL,
support membrane, and receiver) using a custom designed MatLab
routine. Donor and receiver compartments were modeled as con-
tinuously stirred by using a high value for the diffusion coefficient.
Diffusion in the support membrane was defined by the effective
volume-averaged diffusion coefficients Dsup of 7.67× 10−7 cm2/s
(PR-104A), 1.60× 10−6 cm2/s (PR-104H), and 6.95× 10−7 cm2/s
(PR-104M) fitted to support membrane transport data as reported
(39). A one-dimensional time-dependent solution of Eq. 1 was fit-
ted to the MCL transport data with D and ϕi as fitted parameters,
using a MatLab non-linear regression routine, nlinfit, with 100-
fold weighting of receiver compartment data. Here kmetN, k ieN,
and keiN were set at their population mean values (i.e., inter-
and intra-experimental variability was not included in the SR-
PK/PD model) and parameters estimated in an iterative process
until values were found that described both in vitro models.
TUMOR MODELS AND TREATMENT
All animal studies were approved by the University of Auckland
Animal Ethics Committee. Human tumor xenografts were grown
subcutaneously on the right flank of female NIH-III nude mice
(NIH-LystbgFoxn1nuBtkxid; 18–20 g body weight), derived from
breeding mice purchased from Charles River Laboratories (Wilm-
ington, MA, USA), by inoculating 0.5–1× 107 cells. Mice were
stratified to treatment groups when tumors reached volumes of
400–800 mm3. Compounds were administered by intraperitoneal
(i.p.) injection (dose volumes: 0.01–0.02 ml/g). Whole-body irra-
diation (0.35 Gy/min) was performed using a 60Co source. For
modulation of tumor oxygenation, animals breathed 100% O2 at
2.25 atm (hyperbaric oxygen) in a Reimers RSI B11 hyperbaric
chamber (Reimers Systems, USA) or 10% O2/90% N2 at atmos-
pheric pressure (42). Tumors were excised and single cells prepared
by mincing, incubation with enzyme cocktail (2.5 mg/ml pronase,
1 mg/ml collagenase, and 0.2 mg/ml DNAase I) for 30 min at 37°C
and sequential filtration using 100, 70, and 40µm cell strainers
(BD Biosciences, USA). For pharmacokinetic studies, plasma and
tissue was collected and prepared as described (33) with minor
changes: plasma and tissue samples were stored at −80°C before
extraction with cold acidified methanol (as above) containing
0.67µM PR-104-d4, 0.67µM PR-104A-d4, 0.2µM PR-104H-d4,
and 0.2µM PR-104M-d4. Extracts were stored at −80°C, cen-
trifuged (13,000 g, 4°C, 10 min) and supernatants were diluted 1:1
with cold water prior to LC-MS/MS analysis.
CLONOGENIC ASSAY
Single cell suspensions were serially diluted and plated in 5 ml
α-MEM+ 5% FBS+ 1% penicillin/streptomycin in 60 mm cell
culture dishes. Following incubation at 37°C for 11 (HCT116
in vitro samples), 12 (HCT116 tumor samples), or 14 (SiHa sam-
ples) days, dishes were stained with methylene blue and colonies
(>50 cells) were counted to determine PE. Cell SF was determined
as PE (treated)/PE (controls). HCT116/sPOR#6 control cells were
plated in media with and without 3µM puromycin to determine
the proportion of cells retaining puromycin resistance.
LC-MS/MS ANALYSIS OF PR-104 AND METABOLITES
High pressure liquid chromatography with mass spectrometry
detection (LC-MS/MS) of PR-104 and metabolites was performed
using a validated method (14), with the following changes: the
LC-MS/MS system was an Agilent 1100 HPLC interfaced with
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an Agilent 6410 triple quadrupole mass spectrometer equipped
with a multimode ionization source (Agilent Technologies, USA).
Chromatographic separation was achieved on a Zorbax SB-C18
rapid resolution column (50 mm× 3 mm, 1.8µm particles; Agi-
lent Technologies) at 25°C with a 0.2µm in-line filter. The mobile
phase consisted of acetonitrile (A) and 0.01% formic acid in water
with fast gradient elution at a flow rate of 0.4 ml/min and run
time of 7 min. The following gradient was applied: 0 min, 20%
A; 1 min, 20% A; 3.5 min, 40% A; 4 min, 100% A; 5 min, 100%
A; 5.5 min, 20% A. The eluent flow was led into the mass spec-
trometer starting 2 min after injection by switching to the MS
inlet valve. PR-104A absorbance was monitored by photodiode
array detection upstream of the MS/MS at 370 nm (bandwidth
4 nm, reference wavelength 550 nm) and used for PR-104A quan-
tification in in vitro samples with >10µM PR-104A. Multiple
reaction monitoring was used for quantification of PR-104A in
in vitro samples with <10µM PR-104A and in vivo samples, and
for quantification of PR-104, PR-104H, and PR-104M.
Calibration curves were prepared by spiking cold αMEM
(in vitro studies), blank plasma, or blank tissue extracts (in vivo
studies) with PR-104A, PR-104H, PR-104M, and PR-104 (only for
in vivo studies), followed by serial dilution in the respective matrix.
The samples were mixed 1:1 with water (tissue extracts) or with
the same solvent that was used for sample extraction (in vitro and
plasma samples) and stored at−80°C.
FLOW CYTOMETRY
Reduction of FSL-61 by one-electron-reductases was assessed
by flow cytometry as described (43). Staining of EF5 adducts
for flow cytometry was performed using Cy-5-conjugated Elk3-
51 antibody (Prof. CJ Koch, Pennsylvania University; 75µg/ml)
according to a validated protocol (44). Gates for EF5-positive cells
excluded ≥95% of cells from tumors not treated with EF5 but
stained with Elk3-51.
IMMUNOHISTOCHEMISTRY AND MICROSCOPY
Formalin-fixed paraffin-embedded tumor sections were prepared
for immunohistochemistry as reported (42). POR immunostain-
ing was performed using a validated method (19) as described
(42). For dual staining of EF5 and pimonidazole, sections were
incubated with Cy-3-conjugated Elk3-51 antibody (Pennsylva-
nia University; 100µg/ml) for 5 h at 4°C, followed by rinsing
in Tris buffered saline (pH 7.6) containing 0.1% Tween-20, and
incubation with FITC-conjugated anti-pimonidazole antibody
(Hypoxyprobe-1 clone 4.3.11.3, Natural Pharmacia International,
USA; 120µg/ml) for 2 h at room temperature.
For imaging of tumor hypoxia, vasculature, and perfusion,
tumor-bearing male NIH-III nude mice were dosed i.p. with
60 mg/kg EF5. Three hours later, mice were dosed i.v. with
15 mg/kg Hoechst 33342 (Sigma-Aldrich, USA) and sacrificed
2 min later. Tumors were excised, frozen to liquid nitrogen tem-
perature in Tissue-Tek CRYO-OCT compound (Thermo Fisher
Scientific), and stored at −80°C. 10µm sections were cut using a
cryotome, mounted onto glass slides, and stored at −20°C. Fol-
lowing imaging of Hoechst 33342 as below, sections were fixed
in ice-cold acetone for 10 min, blocked with 10% normal goat
serum in PBS (1 h, RT), and incubated with Alexa Fluor 488-
labeled rat monoclonal anti-mouse CD31 antibody (BioLegend,
San Diego, CA, USA; 5µg/ml) overnight at 4°C. After rinsing in
PBS, sections were incubated with Cy-3-conjugated Elk3-51 anti-
body (75µg/ml) for 5 h at 4°C. Slides were then washed in PBS
and counter-stained with 0.5µg/ml DAPI (Invitrogen Molecular
Probes, USA). Whole-section montage images were acquired with
a Nikon TE2000E inverted microscope with a 10× objective, using
a computer-controlled automatic stage (ProscanII; Prior, USA)
and the image acquisition software Image Pro Plus (version 7.1;
MediaCybernetics).
RESULTS
DEVELOPMENT OF SR-PK/PD MODELS FOR THREE CELL LINES
Using the approach illustrated in Figure 1, SR-PK/PD models were
developed for SiHa and HCT116 cells, which have high and low
expression of the aerobic PR-104A reductase AKR1C3 respectively
(22), and for HCT116/sPOR#6 cells engineered to provide a high
rate of PR-104A activation under hypoxia. Notably, the parental
cell lines lack connexin 43 expression (45, 46), thus minimizing
any gap junction-dependent drug diffusion.
The cellular PK model
Firstly the cellular pharmacology of PR-104A was investigated in
single cell suspensions. This showed rapid uptake of PR-104A
into all cell types (Figures 3A–C). The steady-state C i /C e ratio
was ∼1 in SiHa but >1 in the HCT116 cell lines (range 3–7).
Under anoxia PR-104A was converted to the active metabolites PR-
104H and PR-104M, which reached much higher concentrations
within cells than in the extracellular medium with the following
C i/Ce ratios at steady-state (30–180 min): SiHa: 56± 7 (H), 19± 4
(M); HCT116/WT: 160± 9 (H), 140± 6 (M); HCT116/sPOR#6:
100± 8 (H), 160± 10 (M). This indicates that cell membranes
may act as a barrier to the diffusion of PR-104H+M after their
intracellular formation from PR-104A, which could retard their
transport in tissue. We therefore distinguished the intracellular
and extracellular compartments in the SR-PK/PD model by using
a continuum approximation in which transfer between the two
compartments is represented by rate constants keiN and k ieN,
and it is assumed that metabolism is restricted to the intracel-
lular compartment while diffusion is confined to the extracellular
compartment (Figure 2). This cellular PK model contains multi-
ple parameters, which were constrained by the requirement that
they also describe MCL transport data (below). For each cell line,
parameter sets could be found (Table S1 in Supplementary Mater-
ial) that globally fitted the data (shown for single cell suspensions
in Figures 3A–C). Metabolism of PR-104A, PR-104H, and PR-
104M was assumed to follow first-order kinetics because no major
non-linearity was found in cellular PK experiments. The cellular
PK of HCT116/sPOR#6 cells could be described using the same
model as for HCT116/WT apart from a 20.4-fold higher anoxic
PR-104A metabolism rate constant (kmetA,max; 1.8× 10−2 s−1;
Figure 3C), consistent with overexpression of this known (17)
PR-104A one-electron-reductase.
The cellular PK/PD model
To define a cellular PK/PD model, we measured clonogenic cell
killing as the PD endpoint because this is equally applicable to
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FIGURE 3 | PK/PD of PR-104A, PR-104H, and PR-104M in single cell
suspensions (2×106 cells/ml) after addition of PR-104A. Cells were
derived from SiHa monolayers (A,D,G) or from spheroids grown from
HCT116/WT (B,E,H) or HCT116/sPOR#6 cells (C,F,I). (A–C) Concentrations
of intracellular (closed circles, solid lines) and extracellular (open circles,
dashed lines) PR-104A (green), PR-104H (red), and PR-104M (blue) under
anoxia. Symbols represent mean±SEM of concentrations for 4 (B) or 3
(A,C) replicate vials and lines show predictions of the model that best
fitted the experiments overall (including MCL experiments, see Figure 5).
Concentrations (y -axis) are normalized to initial extracellular PR-104A
concentrations (C0) of 10, 60, and 300µM (A), 30µM (n=2) and 40µM
(n=2) (B) or 2, 3, and 5µM (C). (D–I) Measured log cell kill under anoxic
(•) or aerobic conditions (◦) as a function of intracellular (ic) PR-104A AUC
(D–F) or PR-104H+M AUC (G–I). Symbols represent surviving fractions
from individual vials at different time points while lines show linear
regression fits. PR-104H+M PK/PD in HCT116/WT and sPOR#6 (H,I) is
only shown for anoxic conditions because reduced metabolite
concentrations were below the LLOQ under aerobic conditions. In SiHa
single cell suspensions, intracellular concentrations and cell kill were not
measured in the same experiments, therefore intracellular AUC values
were derived from model-estimated instead of measured
concentration-time profiles.
cell cultures and tumor xenografts. Log cell kill in single cell sus-
pensions was linearly dependent on the AUC of PR-104A or its
reduced metabolites (Figures 3D–I), consistent with the linear
relationship between PD and AUC for other alkylating agents (47).
Data for anoxic HCT116/sPOR#6 cells at low survival (>2 log cell
kill) deviated from the linear trend (Figure 3F), which may reflect
the presence of a small fraction of cells with low sPOR expres-
sion and thus lower sensitivity to PR-104A. Consistent with the
hypoxic selectivity of PR-104A activation, PR-104A potency as
quantified by the inverse of AUC for 10% survival (AUC10) was
www.frontiersin.org October 2013 | Volume 3 | Article 263 | 7
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much higher (∼30-fold) under anoxic than aerobic conditions in
SiHa and HCT116 (Figures 3D,E). This differential was greatly
reduced when the AUC of PR-104H+M was used as the exposure
variable, as shown for SiHa cells in Figure 3G. The slightly greater
sensitivity of cells under anoxia was confirmed in SiHa cell sus-
pensions exposed to synthetic PR-104H (Figures 4A,B), but for
simplicity the average of the anoxic and oxic AUC10 values was
used in the SR-PK/PD model.
The (pro)drug transport model
Next, we investigated transport of PR-104A and its metabolites
through MCLs following addition of PR-104A to the donor com-
partment. PR-104A penetration was suppressed by metabolic acti-
vation under anoxia (Figures 5A–C), which was accompanied
by the appearance of PR-104H+M in the receiver compartment
(Figures 5D–F), confirming that these metabolites can diffuse in a
tissue-like environment after their intracellular generation from
PR-104A. Notably, overexpression of sPOR in anoxic HCT116
MCLs increased concentrations of PR-104H+M in the receiver
compartment∼4-fold (Figure 5F), although markedly decreasing
PR-104A penetration (Figure 5C). All data could be described
using the two-compartment model described above, with the
diffusion coefficients (DN) given in Table S1 in Supplementary
Material. The PR-104H diffusion coefficient for SiHa was inde-
pendently determined from measured MCL transport of PR-104H
following its addition to the donor side (Figure 6).
The (pro)drug transport model was used to estimate the pen-
etration half distances (x1/2) of active metabolites, by simulating
their extracellular concentration-distance profiles at steady state
when each compound is maintained at constant concentration on
one side of an infinite planar slab. With this simplified geometry,
x1/2 estimates were 128µm (PR-104H) and 73µm (PR-104M)
in SiHa tissue and 33µm (PR-104H) and 41µm (PR-104M) in
HCT116 tissue. This indicates that reduced metabolites may dif-
fuse through several cell layers, once released from cells where they
were produced.
ESTIMATION OF THE ROLE OF BYSTANDER EFFECTS USING SR-PK/PD
MODELING
To assess the impact of metabolite diffusion on cell killing in
tumors, the above PK/PD parameters were used to calculate pro-
drug/metabolite exposure and resulting cell killing at each point
of a digitized FaDu tumor microregion. By adjusting inflow pO2,
the hypoxic fraction (at<1µM O2) in this region was matched to
the pimonidazole-positive fraction measured in HCT116 tumors
(23.0%) or SiHa tumors (12.3%) in our lab (22). The frequency
distributions of O2 concentrations in the tumor microregion are
shown in Figure S1C,D in Supplementary Material. The spatial O2
distribution in the microregion used to model HCT116 tumors
is shown in Figure 8A. Measured PR-104 plasma PK was used
to define unbound AUC of PR-104A/H/M in all inflowing ves-
sels of the tumor microregion. Notably, the PK was different in
the mouse strains used to grow SiHa tumors [CD-1 nude mice
(33)] and HCT116 tumors [NIH-III nude mice; Figure 7], with
NIH-III nude mice showing ∼fivefold lower levels of circulating
metabolites at equivalent dose. Therefore low-AKR1C3 HCT116
tumors in NIH-III nude mice represent a good model to evaluate
FIGURE 4 | Cellular PK/PD of PR-104H in SiHa cells.
(A) Concentration-time profiles of intracellular (closed circles, solid lines)
and extracellular (open circles, dashed lines) PR-104H in SiHa single cell
suspensions (5×106 cells/ml) following addition of PR-104H under anoxic or
aerobic conditions. Concentrations are normalized to initial concentrations
(C0) of PR-104H. All symbols represent mean±SEM of measured values
for three vials (with C0 of 10, 30, and 100µM) while lines show predictions
of the cellular PK model (see Table S1 in Supplementary Material).
(B) Measured log cell kill under anoxic (•) or aerobic conditions (◦) in the
above experiment as a function of extracellular (ec) PR-104H AUC as
calculated from measured concentration-time profiles shown in (A) (left
panel), or intracellular (ic) PR-104H+M AUC derived from model-estimated
concentration-time profiles (right panel). Lines show linear regression fits.
the impact of bystander effects resulting from PR-104A activation
in hypoxic tumor regions. SR-PK/PD simulations for this tumor
model showed decreasing PR-104A and increasing PR-104H+M
exposure (AUC) with decreasing O2 concentrations (Figure 8B).
The contribution of bystander effects was distinguished by com-
parison of the “no-bystander” and “+bystander” simulations that
relate cell killing to prodrug and metabolite AUC, respectively
(see Eqs 4 and 5). The “+bystander” model predicted higher
killing across the entire tumor microregion (Figure 8C), and
improved complementarity with radiation (Figure 8D). Bystander
effects were estimated to contribute ∼50% of predicted over-
all cell killing in HCT116 tumors grown in NIH-III nude mice
and ∼30% of activity in SiHa tumors grown in CD-1 nude
mice, with very similar estimates for PR-104 monotherapy activity
and killing additional to radiation (Figure 9). Remaining activity
was due to direct killing of prodrug-activating cells and killing
of perivascular cells by circulating metabolites with the contri-
bution of the latter higher in CD-1 nude mice because of the
higher PR-104H+M plasma AUC in this strain. The relative
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FIGURE 5 |Transport of PR-104A and reduced metabolites through MCLs
grown from SiHa, HCT116/WT, or HCT116/sPOR#6 cells. PR-104A was
added to the donor side of MCLs (see Figure 1) under anoxia (closed
symbols, solid lines) or oxia (open symbols, dashed lines). Graphs show
receiver concentrations of PR-104A (A–C), PR-104H [(D–F); red] and PR-104M
[(D–F); blue], normalized to initial donor concentrations (C0) of PR-104A of
300µM (A,D), 650µM (B,E), and 250µM (C,F), and plotted against C /C0 of
the 14C-urea internal standard to adjust for differences in MCL thickness.
Symbols represent measured data for representative MCLs while lines show
predictions of the (pro)drug transport model (Figure 2, Table S1
Supplementary Material) that best fitted the experiments overall (including
cellular PK experiments illustrated in Figure 3).
contribution of overall (direct+ bystander) killing resulting from
O2-sensitive one-electron reduction (30% in SiHa and 55% in
HCT116 tumors) and overall killing arising from O2-insensitive
AKR1C3-mediated two-electron reduction (38% in SiHa and 22%
in HCT116 tumors) was influenced by hypoxic fraction (higher
in HCT116 tumors) and AKR1C3 expression (higher in SiHa
tumors).
EVALUATION OF THE SR-PK/PD MODEL BY COMPARISON OF
MEASURED AND MODEL-ESTIMATED PR-104 ANTITUMOR ACTIVITY
In order to test the predictive ability of the SR-PK/PD model, we
utilized previous data for clonogenic cell killing in SiHa tumors
(20) and also evaluated activity in HCT116 tumors, 18 h after
treatment with two dose levels of PR-104, either alone or imme-
diately after a single radiation dose. Higher PR-104 doses were
tested with HCT116 which was the less sensitive of the two tumor
models (Figure 9). The SR-PK/PD model predictions for over-
all (averaged) cell kill were broadly similar to measured values,
although the model under-estimated killing in SiHa tumors while
over-estimating killing in HCT116 tumors. This might reflect
missing information about the biology of these tumors, or errors
in the model parameters. To evaluate the sensitivity of the HCT116
SR-PK/PD model to parameter errors, we varied each parameter
±50%; this did not change predictions for PR-104 monotherapy
activity by more than 45% in any instance (Figure 10), demon-
strating that the model is reasonably robust. Predictions could be
FIGURE 6 | PR-104H transport through SiHa MCLs. PR-104H was added
to the donor side of oxic SiHa MCLs that had been grown for 2 days only (to
provide relatively thin MCLs; thickness 125± 3µm). Graphs show
measured (symbols) and model-estimated (lines) PR-104H concentrations
on the donor side (left panel) and receiver side (right panel) of representative
MCLs. Model fits used the parameters for PR-104H metabolism, instability,
and membrane transfer estimates given in Table S1 Supplementary
Material and a PR-104H diffusion coefficient of 1.06±0.06×10−6 cm2/s.
matched to experimental results by a 50% decrease in the rate
constant for PR-104A uptake, keiA, which had a relatively high
CV of 32%, or by a 50% decrease in reduced metabolite potency
(1/AUC10H+M; CV 7.3%) and inflow AUC of PR-104A/H/M
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FIGURE 7 | Pharmacokinetics of PR-104A and its reduced
metabolites in NIH-III nude mice. Concentrations of PR-104A (•),
PR-104H (H), and PR-104M () in plasma (A) and HCT116 tumors (B) of
NIH-III nude mice after i.p. administration of 562µmol/kg of PR-104. Data
represent mean±SEM for three to four mice. Numbers in brackets are
values for AUC0–∞ in micromolar·hour as estimated by
non-compartmental analysis using Phoenix WinNonlin (version 6.0;
Pharsight, CA, USA).
FIGURE 8 | SR-PK/PD model predictions for HCT116 tumors following
i.p. administration of 562µmol/kg PR-104. (A) Contour plot of O2 (in
mmHg) in a mid-plane section of the virtual 3D tumor microregion
(990×810×150µm), superimposed with the whole microvascular network
projected onto the plane. Arrows indicate flow direction in the main feeding
arteriole (Art) and the main draining venules (Ven). (B–D) PK/PD as a
function of O2 in the tumor microregion: (B) intracellular AUC of PR-104A
(left y -axis) and PR-104H and PR-104M (right y -axis), (C) Cell kill with and
without a bystander effect, calculated using Eqs 4 and 5, respectively. The
contribution of circulating metabolites was included to the “no-bystander”
model by adding cell kill predicted for circulating PR-104H+M only
(calculated by Eq. 4). (D) Cell kill by 10 Gy radiation (black) or by PR-104 in
combination with radiation. Lines represent averaged cell kill for the whole
tumor microregion. Gray shaded areas mark regions at intermediate O2
concentrations (between 0.13 and 4µM, the KO2 – values for PR-104A and
radiation, respectively).
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FIGURE 9 | Measured (white) and model predicted (colored) PR-104
antitumor activity. (A,B) Monotherapy activity. (C,D) Activity in addition to
radiation. Cell kill was measured in SiHa tumors grown in CD-1 nude mice
[(A,C); data from (20)] and HCT116 tumors grown in NIH-III nude mice (B,D),
18 h after i.p. administration of PR-104 with or without whole-body irradiation
5 min before PR-104 dosing [(C): 15 Gy; (D): 10 Gy]. Data show mean±SEM
for four or five mice. Predicted values represent average log cell kill in the
tumor microregion. Contributions of mechanisms (a–c) were dissected by:
(a) setting plasma PR-104A AUC to 0, (b) relating cell kill to prodrug AUC (Eq.
5), and (c) subtracting (a,b) from total predicted cell kill. Cell kill resulting from
hypoxic (blue) or O2-insensitive (green) PR-104A activation was distinguished
by setting kmetA ,min to 0.
(error estimate not available). Model predictions were also not
highly sensitive to the specific features of the FaDu network; simi-
lar cell killing was predicted when we used a mapped network from
a rat R3230Ac tumor (28) (with O2 inflow adjusted to achieve sim-
ilar oxygenation in the FaDu and R3230Ac networks) even though
the latter network showed 1.8-fold higher total blood inflow per
tissue volume and a 1.5-fold higher median distance to nearest
vessel (Figure S1 in Supplementary Material).
Notably, the model over-estimated PR-104 monotherapy activ-
ity in HCT116 tumors, while providing better predictions of
PR-104-mediated killing additional to radiation with either net-
works (as shown based on the FaDu network in Figures 9B,D).
This might be explained by the presence of large well-oxygenated
regions in HCT116 tumors, which are efficiently killed by radi-
ation but not by treatment with PR-104 alone because they are
beyond the reach of local bystander effects. Imaging of the hypoxia
marker EF5 and the perfusion marker Hoechst 33342 on frozen
tumor sections revealed that HCT116 tumors do indeed con-
tain large well-perfused regions without EF5-staining (>1 mm2;
Figure 11). In SiHa tumors, such large well-oxygenated regions
were less common (Figure 11).
MODULATION OF HYPOXIA AND REDUCTASE ACTIVITY TO FURTHER
EVALUATE THE SR-PK/PD MODEL
The SR-PK/PD model was tested further by modulating two para-
meters to which the model is moderately sensitive (Figure 10).
Firstly, tumors grown from HCT116/sPOR#6 cells were used to
evaluate the effect of increasing the rate constant for anoxic PR-
104A reduction kmetA,max. Average tumor concentrations of PR-
104H+M 30 min after i.p. administration of 562µmol/kg PR-104
were significantly higher in HCT116/sPOR#6 than WT tumors
(Figure 12A), confirming functional expression of sPOR in vivo.
This did not increase plasma concentrations of PR-104H+M,
consistent with earlier studies demonstrating that systemic
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FIGURE 10 | Sensitivity analysis of the PR-104 SR-PK/PD model for
HCT116 tumors. Percentage of change in model-estimated monotherapy
activity (at 562µmol/kg PR-104) resulting from a 50% increase in parameter
values relative to the default model values of Table S1 in Supplementary
Material (y -axis) plotted versus the respective % change in killing resulting
from a 50% decrease in parameter values (x -axis). Symbols represent
individual parameters, with the symbol area proportional to the CV of the
estimated parameter values (highest CV 59.6% for kmetH). No CV estimate
was available for kmetA ,min and AUCN inflow (with N denoting A, H, or M). aNo
predictions were available for a 50% lower parameter value. bNo predictions
were available for a 50% higher parameter value. c The fraction at <1µM O2
was modulated by changing inflow pO2.
exposure to these metabolites is primarily due to hepatic (not
intra-tumor) activation of PR-104A (33). Therefore SR-PK/PD
in HCT116/sPOR#6 tumors was simulated with unchanged drug
inflow AUCs, using a 20.4-fold increased kmetA,max as deter-
mined in HCT116/sPOR#6 cell suspensions. In the model, the
increased metabolic consumption substantially impaired PR-104A
penetration into hypoxic regions (Figure 12B), but increased lev-
els of reduced metabolites throughout the tumor microregion
(Figure 12C), causing ∼2.5-fold higher average predicted cell
kill relative to WT (Figure 12D). In contrast, measured PR-104
monotherapy activity at a dose of 900µmol/kg was not sig-
nificantly different between HCT116/WT and HCT116/sPOR#6
tumors (P = 0.187, t -test; Figure 12D). A likely explanation is
the heterogeneity of sPOR expression in HCT116/sPOR#6 tumors
as demonstrated by immunohistochemistry, with low-sPOR cells
often found at a distance of 100–300µm from high-sPOR cells
(Figure 12E) and thus expected to be beyond the range of
bystander metabolites. Further evidence for heterogeneity of sPOR
expression in vivo includes the lack of puromycin resistance in
approximately one third of cells recovered from HCT116/sPOR
tumors (SF in puromycin medium 67.2± 2.4%,n= 3), suggesting
loss of expression of the bicistronic sPOR-IRES-pac mRNA encod-
ing sPOR and the puromycin resistance gene pac (puromycin
N -acetyltransferase). In addition, anoxic one-electron reduction
of the fluorogenic probe FSL-61 [which correlates with anoxic PR-
104A reduction in tumor cell lines (43)] demonstrated marked
heterogeneity in cells from HCT116/sPOR#6 tumors with ca.
one third having one-electron-reductase activity similar to WT
cells and remaining cells showing FSL-61 fluorescence interme-
diate between WT and sPOR#6 cells in vitro (Figure 12F) As
a simple way of modeling the macroregional heterogeneity, we
assumed that HCT116/sPOR#6 tumors comprise two separate,
non-communicating compartments with kmetA,max equivalent to
sPOR#6 in culture (possibly still over-estimating one-electron
reduction of PR-104A) and at the WT level in a 2:1 ratio. This com-
bined model provided much better prediction of PR-104 activity
in HCT116/sPOR#6 tumors (Figure 12D).
For a further evaluation of the SR-PK/PD model, tumor
hypoxia was modulated by exposing tumor-bearing mice to hyper-
baric oxygen, air or 10% O2 following administration of PR-
104 and/or EF5. The respiratory gasses modulated hypoxia in
HCT116/WT tumors as demonstrated by dual imaging with the
hypoxia markers pimonidazole and EF5 (Figures 13A–C), but did
not significantly change concentrations of PR-104, PR-104A, and
reduced metabolites in plasma (Figure 13D) or liver (Figure 13E)
30 min after i.p. administration of PR-104. This is consistent with
previous data indicating that hepatic metabolism of PR-104A in
mice is independent of hypoxia (33), and suggests that tumor
input of PR-104A and metabolites is unaffected by the respiratory
gases. PR-104 monotherapy activity in HCT116/sPOR#6 tumors
correlated with the EF5-positive fraction (Figure 13F). The com-
bined model introduced above (one third of HCT116/sPOR#6
tumor regions with PR-104A activation similar to WT) predicted
this trend, although over-estimating killing (Figure 13G). Inde-
pendent of the model, the observation that killing was greater
than accounted for by the proportion of EF5-positive cells (e.g.,
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FIGURE 11 | Hypoxia, vasculature, and perfusion in SiHa and HCT116
tumors. Photomicrographs show overlaid images of the perfusion marker
Hoechst 33342 (blue), the hypoxia marker EF5 (red), and the vascular marker
CD31 (green) on frozen sections of SiHa tumors (A–D) and HCT116
tumors (E–G). Inset pictures show DAPI nuclear staining on the same (E–G)
or adjacent sections (A–D). Areas of necrosis are encircled by white lines.
s, stromal connective tissue; *large well-perfused regions. Scale bars
represent 1 mm.
1 log cell kill, i.e., 90% killed fraction at an EF5-positive frac-
tion of ∼40%; Figure 13F) can be considered further evidence for
bystander effects.
DISCUSSION
Our data clearly demonstrate that the active metabolites of PR-
104A can efflux from cells (Figures 3A–C), as previously reported
(13), and are able to diffuse through tissue-like MCLs following
their addition to extracellular medium (Figure 6) and following
their production from PR-104A in anoxic MCLs (Figures 5D–F).
The experimental observations alone, however, do not indicate
the extent to which these diffusible metabolites contribute to anti-
tumor activity. Consequently, we developed a SR-PK/PD model
that calculates the spatial distribution of PR-104A, its metabolites
and their pharmacodynamic effect in a realistic tumor microre-
gion. The model considers intra- and extracellular compartments
to account for cell membranes acting as a barrier to the diffusion
of active metabolites after their intracellular formation from PR-
104A. Using this model, we have shown that bystander effects play
a major role in PR-104 activity in tumor xenografts (Figure 9). The
contribution of bystander effects was distinguished by comparison
of the “no-bystander” and “+bystander” simulations that relate
cell killing to prodrug and active metabolite AUC, respectively
(Eqs 4 and 5), according to the PK/PD relationships determined
in single cell suspensions. The “no-bystander” model predicted
less killing across the entire tumor microregion, even in the most
hypoxic regions (Figure 8C), which may seem surprising given
that cell kill in anoxic single cell suspensions could be predicted
equally well using the PR-104A or metabolite PK/PD relationships
(Figures 3E,H). This difference is a consequence of the failure of
the “no-bystander” model to account for the cell density depen-
dence of killing that follows from the ability of active metabolites
to diffuse out of PR-104A-activating cells, leading to a local rise
of metabolite concentrations in tumor tissue relative to single cell
suspensions. These short-scale bystander effects (diffusion across
the plasma membrane and uptake by adjacent cells) and medium-
scale bystander effects (diffusion to better-oxygenated regions; in
the current model, paracellular only) improved complementary
killing by PR-104 and radiation by partially compensating for
inefficient PR-104A activation at O2 concentrations low enough
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FIGURE 12 | Effect of POR overexpression on PR-104 PK/PD.
(A) Concentrations of PR-104A, PR-104H, and PR-104M in tumor and
plasma 30 min after i.p. administration of 562µmol/kg PR-104 to NIH-III
nude mice with HCT116/WT tumors (blue) or HCT116/sPOR#6 tumors
(red). Data represent mean±SEM for four to five mice. N.S. not
significant; ***P <0.001, t -test. (B,C) SR-PK/PD model predictions for
HCT116/WT and HCT116/sPOR#6 at a PR-104 dose of 900µmol/kg.
Graphs show the distribution of intracellular PR-104A AUC (B),
intracellular PR-104H+M AUC and resulting cell kill (C) as a function of
O2 in the tumor microregion. (D) Predicted average log cell kill for
HCT116/WT, HCT116/sPOR#6, and a combined model with a 1:2 ratio of
WT and sPOR#6 in separate regions (see text). Symbols represent
measured killing in individual tumors 18 h after i.p. administration of
900µmol/kg PR-104, with a line marking the mean. (E) Histological
section of a representative HCT116/sPOR#6 tumor showing POR
immunostaining. Areas of necrosis are marked with N. Scale bar is
1 mm. (F) Representative flow cytometry histograms of cells from
monolayer culture (in vitro) or from tumor xenografts (in vivo) after
incubation with 300µM FSL-61 for 3 h under anoxic conditions (blue: WT,
red: sPOR#6) or as a control under aerobic conditions (black, WT).
to cause radioresistance (∼0.1–4µM O2; Figure 5D). There are
potentially also larger-scale blood-borne bystander effects result-
ing from diffusion of active metabolites into blood vessels and
killing of perivascular cells in downstream tumor regions.
Overall clonogenic killing in tumors estimated by the SR-
PK/PD model was in broad agreement with measured values,
although the model under-predicted activity in SiHa tumors and
over-predicted killing in HCT116 tumors (Figure 9). The fact that
the model was biased in opposite directions for HCT116 and SiHa
tumors suggests that the discrepancies are due to biological factors
that differ between the two tumor types, and that are not currently
captured by the model. One possible missing element is the appar-
ent O2-dependence of reduced metabolite potency in SiHa cells
(Figure 3G), which warrants further investigation. Other factors
could include differences between model parameters in vivo rela-
tive to those determined in vitro. Parameters in question are KO2
(given theoretical arguments that KO2 may be cell density depen-
dent (9), although this has yet to be tested experimentally) and
the parameters for PR-104A metabolism and cellular sensitivity to
active metabolites (e.g., due to potential differences in expression
of PR-104A reductases and DNA damage response pathways in
tumors versus in vitro). However,preliminary experiments showed
that PR-104A metabolism and cytotoxicity is similar in cells from
in vitro culture and from tumor xenografts despite slight apparent
differences in AKR1C3 protein expression (Figure S3 in Supple-
mentary Material). An additional factor we have considered is
possible intra-tumor generation of PR-104A from PR-104 or from
its O-β-glucuronide PR-104G (which is a minor metabolite in
mice but the major PR-104 metabolite in humans (48). Stud-
ies with oxic SiHa MCLs demonstrate that PR-104A is generated
from PR-104, but not from PR-104G (Figure S4 in Supplementary
Material). Thus intra-tumor PR-104 hydrolysis could potentially
increase PR-104A exposure in the tumor although this is unlikely
to fully account for the∼twofold underprediction of PR-104 activ-
ity in SiHa tumors, given that the PR-104 AUC constitutes only
∼30% of the PR-104A AUC in plasma of CD-1 nude mice dosed
i.p. with PR-104 (15).
Finally, the FaDu tumor microregion used in the SR-PK/PD
model has a specific microvascular geometry and blood flow dis-
tribution that may not represent that of SiHa and HCT116 tumor
xenografts. However, in the only other digitized tumor microvas-
cular network with measured blood flows, based on a mapped
region of a rat R3230Ac tumor (28), log cell kill predictions were
within 24% of those for the FaDu network (Figure S1 in Sup-
plementary Material). A greater limitation of both microregions
may be their small volume (0.12 mm3 for FaDu and 0.066 mm3 for
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FIGURE 13 | Effect of O2 modulation on cell killing in
HCT116/sPOR#6 tumors. (A–C) Overlay of micrographs of the hypoxia
markers EF5 [red; reporting hypoxia during treatment with (A) hyperbaric
oxygen (HBO), (B) air, or (C) 10% O2] and pimonidazole (green; reporting
pre-existing hypoxia) from representative sections of HCT116/WT
tumors. Tumor-bearing NIH-III nude mice were dosed i.p. with 60 mg/kg
pimonidazole 2 h prior to i.p. administration of 60 mg/kg EF5 followed by
treatment with respiratory gasses for 1.5 h. Scale bars are 300µm.
(D–G) PR-104 PK and PD as assessed after co-administration of
562µmol/kg PR-104 and 30 mg/kg EF5 i.p. to tumor-bearing NIH-III nude
mice, followed by treatment with HBO (green), air (yellow), or 10% O2
(red) for 30 min (D,E) or 2 h (F,G). (D,E) Concentrations of PR-104 and
metabolites in plasma (D) and liver (E). Data represent mean±SEM for
five (air+ 10% O2) or six mice (HBO). (F) Log cell kill in individual tumors
as a function of EF5-positive fraction, with linear regression line.
(G) mean±SEM of the data shown in F (measured) and estimates
calculated by the combined model for HCT116/sPOR#6 tumors
(predicted; see Figure 12 legend), with oxygenation in the virtual tumor
microregion for each condition adjusted to achieve a fraction of cells
<1µM O2 corresponding to the mean EF5-positive tumor fraction
measured in this experiment (see Figure S2 in Supplementary Material
for frequency and distribution of O2 concentrations).
R3230Ac) that does not adequately account for macroregional het-
erogeneity in tumor oxygenation. Importantly, such heterogeneity
was observed in HCT116 tumors, showing large well-perfused
areas without EF5-staining (>1 mm2; Figure 11), in which cells
are expected to be killed by radiation but not by treatment with
PR-104 alone. This might account for the better prediction of
PR-104 activity when combined with radiation (which will be
effective against these extended oxic regions) in HCT116 tumors
(Figures 9B,D). Larger-scale networks with mapped spatial dis-
tributions of hypoxia would be required to improve SR-PK/PD
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modeling in the future. In addition, a complete description would
need to consider the implications of cycling hypoxia (49), which is
not currently incorporated in the steady-state SR-PK/PD model.
The results of this study have several implications for the
clinical use of PR-104. Firstly, the finding that O2-sensitive and O2-
insensitive PR-104A activation pathways make comparable contri-
butions to PR-104 monotherapy activity (Figure 9) argues for the
use of biomarkers of both pathways (expression of AKR1C3, and
one-electron-reductases in hypoxic cells) in the context of PR-104
therapy. Secondly, the correlation between PR-104 monotherapy
activity and EF5-positive fraction in HCT116/sPOR#6 tumors
(Figure 13F) confirms the dependence of PR-104 activity on
hypoxia-selective PR-104A activation and suggests that EF5 or
other 2-nitroimidazole hypoxia probes could potentially be used
as predictive biomarkers for PR-104. In this context, the 2-
nitroimidazole probes may be acting as reporters of one-electron-
reductase activity as well as hypoxia, as demonstrated for the tira-
pazamine analog SN30000 (42). Thirdly, MCL data (Figures 5C,F)
and SR-PK/PD predictions (Figures 12B–D) for HCT116/sPOR#6
suggest that PR-104 can be applied in human tumors with
high expression of one-electron-reductases without the result-
ing limitation on PR-104A penetration compromising thera-
peutic activity. Fourthly, the lack of a significant difference in
PR-104 monotherapy activity between HCT116/WT tumors and
HCT116/sPOR#6 tumors (with non-uniform sPOR expression;
Figure 12), implies that high one-electron-reductase activity will
not increase PR-104 antitumor activity if there is macroregional
heterogeneity in expression over spatial scales exceeding those of
bystander effects. A full treatment of this problem would require
mapping of spatial heterogeneity of reductases, which is likely to
be an important issue in human tumors given the heterogeneity
of POR expression in histological sections of individual human
tumors (19). Finally, macroregional variations in hypoxia are likely
to limit the reach of bystander effects, implying that local diffu-
sion of active metabolites will not eliminate the need to combine
PR-104 (or other HAP) with agents that provide complementary
killing of aerobic cells.
To our knowledge this is the first study to model bystander
killing in tumor tissue based on measured parameters for
metabolism, diffusion and cytotoxicity of prodrug metabolites.
Unlike a purely experimental approach, SR-PK/PD modeling has
the potential to dissect the parameters underlying tissue pen-
etration of a prodrug and its metabolites, thus providing an
opportunity to identify features that could be optimized by drug
design.
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